iBio Reports Q1 Fiscal Year 2027 Financial Results and Provides Corporate Update

Presented additional preclinical data supporting IBIO-610’s potential to drive fat selective weight loss in combination with GLP-1 therapyCompleted dosing in the single ascending dose portion of the Phase 1 clinical trial of IBIO-600Plans to participate in upcoming scientific and investor conferenc…